Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
05/23 PFIZER : Merck`s Keytruda nabs I-O`s third bladder cancer approval this month
05/23 ABLYNX : Novel nanobody to start clinical development in osteoarthritis - Ablynx..
05/22 MERCK : ‘It’s not you. It’s your thyroid.’ Campaign Laun..
05/22 MERCK : Acquisition of Merck and Millipore brands.
05/19 MERCK : 100 Healthy Years – Are Kids Prepared?
05/18 MERCK : EpiThany Announces Clinical Collaboration with Merck KGaA, Darmstadt, Ge..
05/18 LIQUID CRYSTALS FOR NEW OPTICAL APPL : Merck Collaborates with the University of..
05/18 MERCK : Continues to Grow Profitably in the First Quarter
05/18DJMERCK : Beats Expectations, Guidance Cautious -- Market Talk
05/18DJMERCK : 1Q Net Profit Falls 12%
More news
Sector news : Specialty & Advanced Pharmaceuticals
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
05/18 Merck's (MKGAF) on Q1 2017 Results - Earnings Call Transcript
05/18 Merck KGaA reports Q1 results
05/15 Turmoil In Immuno-Oncology
05/10 Tecentriq Failure Puts Accelerated Approval In A Spin
05/10 Physicians Look For Progress In Mesothelioma
Advertisement
Financials (€)
Sales 2017 15 596 M
EBIT 2017 3 318 M
Net income 2017 1 865 M
Debt 2017 9 690 M
Yield 2017 1,21%
P/E ratio 2017 24,23
P/E ratio 2018 20,75
EV / Sales 2017 1,49x
EV / Sales 2018 1,32x
Capitalization 13 616 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 112 €
Spread / Average Target 6,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA6.25%15 218
ABBVIE INC5.49%105 137
KYOWA HAKKO KIRIN CO L..23.86%10 371
JAZZ PHARMACEUTICALS P..38.59%9 071
CONVATEC GROUP PLC38.95%8 206
ZHANGZHOU PIENTZEHUANG..19.65%4 761
More Results